Tests izalontamab brengitecan against chemotherapy in lung cancer after EGFR drug failure
Tests izalontamab brengitecan against platinum chemotherapy in adults with EGFR-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Key facts
- Where
- Berlin, Chemnitz, Cologne, Donauwörth, Esslingen am Neckar, Gauting, Hamburg, Heidelberg, Kassel, Kiel, Oldenburg, Stuttgart, and Ulm, GermanySee the 14 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-squamous non-small cell lung cancer with an EGFR mutation, whose disease got worse on a 3rd-generation EGFR-TKI medicine.
- Age
- 18 years or older
- Sex
- Women and men can both join.
- Disease stage
- Non-squamous non-small cell lung cancer that cannot be treated with the aim of removing all of the disease. The disease has progressed on the most recent EGFR-TKI treatment.
- Earlier treatment
- The most recent treatment must have been a 3rd-generation EGFR-TKI (such as osimertinib, furmonertinib, lazertinib), alone or combined. The person must be able to have platinum-based chemotherapy with cisplatin or carboplatin plus pemetrexed.
- Biomarker or test result
- A documented EGFR mutation: exon 19 deletion or L858R mutation.
Main reasons for not taking part
- Poor organ function or bone marrow reserve
- Leptomeningeal metastases or spinal cord compression
- Poorly controlled general medical conditions
Read by machine on 9 November 2026.
Where in Germany
- BerlinBerlin, GermanyNot yet recruiting
- ChemnitzChemnitz, GermanyNot yet recruiting
- CologneCologne, GermanyNot yet recruiting
- DonauwörthDonauwörth, GermanyNot yet recruiting
- Esslingen am NeckarEsslingen am Neckar, GermanyNot yet recruiting
- Esslingen am NeckarEsslingen am Neckar, GermanyNot yet recruiting
- GautingGauting, GermanyNot yet recruiting
- HamburgHamburg, GermanyNot yet recruiting
- HeidelbergHeidelberg, GermanyNot yet recruiting
- KasselKassel, GermanyNot yet recruiting
- KielKiel, GermanyNot yet recruiting
- OldenburgOldenburg, GermanyNot yet recruiting
- StuttgartStuttgart, GermanyNot yet recruiting
- UlmUlm, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07100080
- Record updated
- 9 October 2026
- Original description
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI TherapyRead full original descriptionShow less
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Inclusion: Non-squamous NSCLC, not amenable to treatment in curative intent; Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation); Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting; Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Exclusion: Poorly controlled systemic medical conditions; Inadequate organ function and/or bone marrow reserve; Leptomeningeal metastases or spinal cord compression; Other protocol-defined inclusion/exclusion criteria apply.